OxPAPC

TLR2 and TLR4 inhibitor

OxPAPC is generated by the oxidation of 1-palmitoyl-2-arachidonyl-sn- glycero-3-phosphorylcholine (PAPC), which results in a mixture of oxidized phospholipids containing either fragmented or full length oxygenated sn-2 residues.

OxPAPC has been shown to inhibit the signaling induced by bacterial lipopeptide and lipopolysaccharide (LPS).

It acts by competing with CD14, LBP and MD2, the accessory proteins that interact with bacterial lipids, thus blocking the signaling of TLR2 and TLR4 [1, 2].

References:

1. Erridge C. et al., 2008. Oxidized Phospholipid Inhibition of Toll-like Receptor (TLR) Signaling Is Restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition. J. Biol. Chem., 283: 24748-24759.
2. von Schlieffen E. et al., 2009. Multi-Hit Inhibition of Circulating and Cell-Associated Components of the Toll-Like Receptor 4 Pathway by Oxidized Phospholipids. Arterioscler Thromb Vasc Biol, 29: 356-362.

Specifications

Working concentration: 30 µg/ml

Endotoxin level: <0.125 EU/mg

Solubility: 1 mg/ml in culture medium or chloroform

Contents

OxPAPC is provided as a solid.

• 2 x 0.5 mg OxPAPC

OxPAPC is shipped at room temperature.

Store at -20°C.

Solid product is stable 1 year at -20°C.

Aliquots of OxPAPC resuspended in chloroform can be stored at -70°C for 3 months.

Avoid repeated freeze-thaw cycles.